Actively Recruiting
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Led by Jiangsu HengRui Medicine Co., Ltd. · Updated on 2025-06-03
66
Participants Needed
1
Research Sites
88 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This is a single-arm imaging study using DOTATOC peptide, labelled with the Gallium (68Ga) tracer.
CONDITIONS
Official Title
Gallium (68Ga) Edotreotide PET/CT for Imaging Patients With Gastrointestinal Pancreatic Neuroendocrine Tumors
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Able and willing to provide a written informed consent
- 18 to 75 years old, male or female
- ECOG performance status 0 or 1
- Confirmed or suspicion of gastrointestinal pancreatic neuroendocrine tumor (GEP-NET)
You will not qualify if you...
- Unable to lie flat for the entire imaging duration (e.g., persistent cough, claustrophobia, severe arthritis), or unable to enter the PET/CT device
- Planning to be pregnant or currently lactating
- Having active infections or unexplained fever above 38.5 0C lasting more than 1 hour during screening or before receiving the study drug
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Beijing Cancer Hospital
Beijing, Beijing Municipality, China, 100142
Actively Recruiting
Research Team
P
Pan Huang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
DIAGNOSTIC
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here